| 6.26 0.25 (4.16%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.86 | 1-year : | 10.35 |
| Resists | First : | 7.59 | Second : | 8.86 |
| Pivot price | 6.25  |
|||
| Supports | First : | 5.5 |
Second : | 4.21 |
| MAs | MA(5) : | 5.85 |
MA(20) : | 6.09 |
| MA(100) : | 4.77 |
MA(250) : | 5.03 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 30.3 |
D(3) : | 25.9 |
| RSI | RSI(14): 60.2 |
|||
| 52-week | High : | 8.81 | Low : | 3.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DTIL ] has closed below upper band by 49.8%. Bollinger Bands are 31.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.4 - 6.42 | 6.42 - 6.44 |
| Low: | 5.68 - 5.7 | 5.7 - 5.72 |
| Close: | 6.22 - 6.25 | 6.25 - 6.29 |
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Thu, 02 Apr 2026
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Mon, 23 Mar 2026
Q1 EPS Estimate for Precision BioSciences Raised by Analyst - MarketBeat
Sat, 21 Mar 2026
If You Invested $1,000 in Precision Biosciences (DTIL) - Stock Titan
Wed, 18 Mar 2026
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call - Slideshow (NASDAQ:DTIL) 2026-03-18 - Seeking Alpha
Fri, 13 Mar 2026
Jefferies cuts Precision BioSciences stock price target on valuation - Investing.com
Thu, 12 Mar 2026
Inside Precision Bio's push on hepatitis B and DMD gene editing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 1.913e+007 (%) |
| Held by Institutions | 5.3 (%) |
| Shares Short | 1,480 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.068e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -133.5 % |
| Operating Margin | 36.5 % |
| Return on Assets (ttm) | -22.5 % |
| Return on Equity (ttm) | -62.8 % |
| Qtrly Rev. Growth | 5 % |
| Gross Profit (p.s.) | 197.8 |
| Sales Per Share | 2.59545e+007 |
| EBITDA (p.s.) | 2.59545e+007 |
| Qtrly Earnings Growth | -3.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -66 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.15 |
| Dividend | 0 |
| Forward Dividend | 1.4e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|